section name header

Pronunciation

NAY-doe-lole

Classifications

Therapeutic Classification: antianginals, antihypertensives

Pharmacologic Classification: beta blockers

Indications

REMS


Unlabeled Use:
  • Arrhythmias.
  • Migraine prophylaxis.
  • Tremors (essential, lithium-induced, parkinsonian).
  • Aggressive behavior.
  • Antipsychotic-associated akathisia.
  • Situational anxiety.
  • Esophageal varices.

Action

  • Blocks stimulation of beta1 (myocardial) and beta2 (pulmonary, vascular, and uterine) receptor sites.
Therapeutic effects:
  • Decreased heart rate and BP.

Pharmacokinetics

Absorption: 30% absorbed after oral administration.

Distribution: Minimal penetration of the CNS.

Metabolism/Excretion: 70% excreted unchanged by the kidneys.

Half-Life: 10–24 hr ( in renal impairment).

Time/Action Profile

(anithypertensive effects)

ROUTEONSETPEAKDURATION
POup to 5 days6–9 days24 hr



With chronic dosing.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: ARRHYTHMIAS, BRADYCARDIA, HF, orthostatic hypotension, peripheral vasoconstriction, PULMONARY EDEMA

Derm: itching, rash

EENT: blurred vision, dry eye, nasal stuffiness

Endo: hyperglycemia, hypoglycemia

GI: constipation, diarrhea, nausea

GU: erectile dysfunction, libido

MS: arthralgia, back pain, muscle cramps

Neuro: fatigue, weakness, anxiety, depression, dizziness, drowsiness, insomnia, memory loss, mental status changes, nightmares, paresthesia

Resp: bronchospasm, wheezing

Misc: drug-induced lupus syndrome

Interactions

Drug-drug:

Route/Dosage

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Corgard